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Abstract. Schizophrenia is a chronic disease that requires relatively high treatment costs [1]. 
Several studies have found that atypical antipsychotics are more effective compared to typical 
antipsychotics. As a result, the duration of treatment and the patients’ length of hospital stay 
will be shorter which ultimately reduce the overall treatment costs.  Therefore, it is necessary to 
conduct a cost-effectiveness analysis (CEA) of the two classes of antipsychotic drugs in the 
treatment of schizophrenia inpatients admitted to  Jambi Province Hospital period 2013-2016. 
Method: This descriptive retrospective cohort study was undertaken to analyze cost-
effectiveness of the antipsychotic drugs provided to patients with schizophrenia (n=910) 
admitted to Jambi Province Hospital from the perspective of a healthcare provider. using 
purposive sampling technique. Characteristics of the patients, antipsychotic drugs usage, costs 
consumed, and treatment outcome were extracted from the hospital databases. Results: It was 
found that the total ACER value of the typical antipsychotic group was Rp. 142,789.25 and 
atypical antipsychotics is IDR 163,045.50 which indicates that the typical ACER antipsychotic 
value is  smaller than  those of atypical antipsychotics based on the length of stay of patients in 
the Psychiatric Intensive Care Unit (PICU) room. Whereas based on the PANSS-EC score of 
the patient, the total ACER value of the typical antipsychotic group was IDR1,189,910.42 and 
in atypical antipsychotics was IDR. 572,089.47. Conclusion: Atypical antipsychotics are more 
cost-effective than typical antipsychotics. 
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1. Introduction 
Cost-effectiveness analysis is considered necessary to be carried out in order to assist in making 
decisions on effective drug selection in terms of benefits and costs [2]. Pharmacoeconomic analysis 
methods such as Cost-Effectiveness Analysis (CEA) can be used to determine whether a drug is 
sufficient to be offered and used in health services [3]. Cost-effective drug selection allows the
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rational use of health care funds  so that the quality and scope of services can be further enhanced 
[4]. In 2013, O’Day, Rajagopalan, Meyer, Pikalov, & Loebel conducted research on cost-
effectiveness of  atypical antipsychotics and found that the cost-effectiveness of lurasidone was 
better than that of generic atypical antipsychotics (risperidone, ziprasidone, and olanzapine) and 
atypical branded antipsychotics (extended-release quetiapine and aripiprazole). Other study 
suggested  that atypical antipsychotics were more cost effective compared to first-generation 
antipsychotics (haloperidol). Additionally,  in 2015, Adriana et al, concluded that atypical 
antipsychotics were more cost-effective than typical antipsychotics. [7]. 
Most of the previous studies that have been carried out generally  focused on comparing  two 
antipsychotic therapies by measuring length of stay as the effectiveness measure of schizophrenia 
treatment. . For this reason, an assessment of PANSS-EC (Positive and Negative Syndrome Scale 
Component) is needed to measure the effectiveness of a drug to treat schizophrenia. PANSS is a 
rating scale of positive, negative, and general psychopathology in schizophrenia patients that can be 
used to indicate psychotic symptoms related to treatment targets and accurately and validly predict 
the patient's response to the treatment given. PANSS-EC is an indicator of restless rowdy patients  
also used to quickly treat restless rowdy patients [8]. 
Based on the  above facts,  this study analyzed the cost-effectiveness of  antipsychotics in 
schizophrenia patients  by measuring  PANSS-EC scores as the treatment effectiveness. 
2. Methods 
2.1 Place / Location and Time of Research 
This research was conducted at the Regional Mental Hospital of the Province of Jambi medical 
record section from November 2017 to March 2018.  
2.2 Types of Research 
This research was a descriptive study with retrospective data, the researcher used a purposive 
sampling technique.  
2.3 Population and Research Sample 
The population in this study is medical records of schizophrenia patients who use antipsychotics in 
the inpatient installation of the Jambi Provincial Hospital. The research sample was medical records 
of schizophrenic patients in 2013-2016 with inclusion criteria: medical records of patients who were 
newly registered in the inpatient installation of Jambi Provincial Hospital in 2013-2016; Patients 
who are diagnosed with schizophrenia in their medical records; Medical records of patients taking 
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typical antipsychotics (haloperidol, chlorpromazine, and fluphenazine-decanoate) and / or atypical 
(risperidone, olanzapine and clozapine) until cured; Complete and clearly read patient medical 
records. And exclusion criteria: Medical records of patients with complications of the disease; 
Medical record of patients who are discharged with their own will/family; Medical record of 
patients who experience recurrence after being declared cured. 
2.4 Data Sources 
Data of patients with schizophrenia in 2013-2016 included patient medical records and drug price 
lists as well as a list of prices for inpatient services at the Jambi Provincial Hospital. 
2.5 Research Procedures 
2.5.1 Sampling 
Sampling was done by searching the medical records of patients who were hospitalized with 2013-
2016 data. Data taken are a patient name; medic record number; age; gender; length of stay; 
Antipsychotic use; Antipsychotic fees; average patient PANSS-EC score; doctor's cost of action; 
maintenance costs during the PICU room. 
2.5.2 Data processing 
Editing: Performed by re-checking the completeness of the data obtained from medical record 
sheets in the inpatient installation of Jambi Provincial Hospital; Entry Data: Transfer of data from 
the basic data sheet and the use of antipsychotic sheets and data entered into the EXCEL program; 
Cleaning: Performed by re-checking the data that has been entered into the EXCEL program for 
further data processed based on their needs. 
2.6 Data Analysis 
Cost-effectiveness analysis was undertaken by calculating the cost-effectiveness ratio (CER) and 
incremental cost-effectiveness ratio (ICER). The data is tabulated based on the type of data 
collected in the medical record room of the Jambi Province Regional Mental Hospital including the 
cost of antipsychotic drugs used by patients; physicians' cost of action; maintenance fees in the 
PICU room; the length of treatment for schizophrenia patients while in the PICU room; Patient 
PANSS-EC score to analyze effectiveness; calculation of the cost-effectiveness of using 
antipsychotics which will then be analyzed using a cost-effectiveness table; Cost-effectiveness 
analysis using the following formula: 
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Effectiveness = 
                    
             
        (1) 
ACER = 
                   
                                 
   (2) 
ICER = 
            –          
                                      
   (3) 
3. Results and Discussion 
Based on the results of a preliminary study at the Jambi Provincial Mental Hospital, the number of 
schizophrenia patients period 2013 to 2016 reached about hundreds to thousands of patients each 
year, with the highest number of patients in 2014 totaling 3,197 patients with temporary 
schizophrenia, schizotypal disorders, and acute psychotic disorders. From the results of data 
collection, researchers obtained 916 patients who met the inclusion criteria.  
3.1 Results 
3.1.1 Overview of research subjects 
The results of the study in the inpatient installation of the Jambi Provincial Hospital received more 
male patients compared to 68.67% for women while 31.33% for women. Based on age range, most 
patients were in the age range of 17-25 years and the lowest was in the age range of 65>. Then 
based on the level of education, most patients were with elementary education level and the lowest 
was the D2 education level.[9] Data can be seen in Table 1. 
Table 1. Characteristics of the Patients 
Characteristics Total Percentage (%) 
Gender 
  Male  
 
629  68.67 
Female  287  31.33 
Age (years) 
  17-25 
 
352 38.43 
26-35 
 
308 33.62 
36-45 
 
161  17.58 
46-55 
 
73 7.97 
56-65 
 
16  1.75 
 ≥65 
 
6 0.655 
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Level of education 
  Uneducated  227 24.78  
SLB 
 
2 0.22 
elementary 
 
306 33.41 
Junior High School 
 
168  18.34 
Senior High School 
 
198  21.62 
Diploma2 
 
1  0.11 
Diploma3 
 
7  0.76 
Bachelor 
 
7  0.76 
3.1.2 Cost Description of the Effectiveness of the Use of Typical Antipsychotic Drugs 
Based on the results of schizophrenia research in the inpatient installation of the Jambi Provincial 
Hospital, patients with typical antipsychotics were 479 patients or 52.29%. Data can be seen in the 
following table: 
Table 2. Utilization of Antipsychotic Medications based on Class Therapy 
Class Total Percentage 
 Typical 479  52.29 
 Atypical 437 47.71 
 
Typical antipsychotic usage cost data obtained an average of Rp. 19,773 where the highest cost is in 
combination with flufenazinedecanoate because flufenazinedecanoate is an antipsychotic in the 
form of ampoules with a quite expensive cost of Rp. 72,500 / ampoule. Then the cost of 
hospitalization in the PICU room has obtained an average of Rp. 522,634.08 per treatment period. 
While the cost of the doctor's action was obtained an average of Rp.28,750. So that a total average 
cost of Rp. 571.157 (table 3). 
Table 3. Cost Typical Antipsychotics 
Class Antipsychotics Drugs 
Average 
Cost 
Cost PICU 
(IDR) 
Average Cost of 
Doctor's 
Actions 
(IDR) 
Average 
Total 
Cost 
(IDR) 
Typical Halo 1,748 524,347.83 25,000 551,096 
 
CPZ 421 505,000 25,000 530,421 
Typical + 
Typical 
Halo + CPZ 2,208 529.859 25,000 557,067 
 
Halo + CPZ + 
Fluf 
74,714 531,329.48 40,000 646,043 
Average 
 
19,773 522,634.08 28,750 571,157 
 
Antipsychotics consumed by patients can affect the length of stay of patients in the PICU room 
where from 479 patients using typical antipsychotics, the average length of stay for patients in the 
PICU room was 4 days (table 4). 
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Table 4. The average stay of PICU with Typical Anti Antipsychotics 
Class Antipsychotic The average stay of PICU 
Typical Halo 4.4 
 CPZ 4.2 
Typical + Typical Halo + CPZ 4 
 Halo + CPZ + Fluf 4.4 
Average  4.25 
 
In addition to being assessed based on length of stay, the effectiveness of therapy can also be 
assessed by PANSS-EC (Positive and Negative Syndrome Scale-Excited Components). In patients 
with typical antipsychotics, the average PANSS-EC score is 22. Data can be seen in table 5 below: 
Table 5. Average PANSS-EC score of Typical Antipsychotics 
Class Antipsychotic 
Average 
PANSS score 
Typical Halo 23,39 
 CPZ 22,71 
Typical + Typical Halo + CPZ 21,5 
 
Halo + CPZ + Fluf 20 
Average 
 
22 
 
3.1.3 Cost Description of the Effectiveness of the Use of Atypical Antipsychotic Drugs 
Antipsychotic cost data has obtained an average of Rp. 12,052, the average cost of 
treatment in the PICU room was Rp. 289,039.25, and the average cost of the doctor's action 
was Rp. 25,000. so that the average total cost of Rp.326,091 was obtained. Data can be seen 
in the following table: 
Table 6. Cost Atypical Antipsychotics 
Class  
Drug 
name 
Average 
cost 
Average of Care 
cost 
Average Cost of 
Doctor's Actions 
Average of 
the total cost 
Atypical Risp 14.182 293.425 25.000 332.607 
 
Olz 11.248 281.194 25.000 317.442 
 
Cloz 4.362 290.769 25.000 320.131 
Atypical + 
Atypical 
Risp + 
Cloz 
18.415 290.769 25.000 334.184 
Average 
 
12.052 289.039,25 25.000 326.091 
Table 7. Average of Long Of Stay at PICU atypical drugs 
Class Antipsychotic  
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Average of Long Of Stay at PICU  
Atypical Risp 2.4 
 
Olz 2.3 
 
Cloz 2.4 
Atypical + Atypical Risp + Cloz 2 
Average 
 
2.275 
Table 8. Average PANSS-EC score of  atypical 
Class Antipsychotic 
Average 
Skor PANSS 
Atypical Risp 19.38 
 
Olz 19.01 
 
Cloz 19.04 
Atypical + Atypical Risp + Cloz 18.5 
Average 
 
18.9825 
 
3.1.4 Calculation of the Effectiveness of the Cost of Using Antipsychotic Therapy 
Comparison of the use of antipsychotics based on an analysis that is more cost effective 
based on length of stay in the PICU room or based on PANSS-EC score is atypical 
antipsychotic. 
The ACER value of the total cost of atypical antipsychotic use based on the effectiveness of 
the length of stay in the PICU room was Rp. 163,045.5 and atypical antipsychotic Rp. 
145,789.25 (table 9). ACER value for the cost of antipsychotics using atypical 
antipsychotics based on length of stay in the PICU room is Rp. 0626 and atypical 
antipsychotic Rp.4,943.25 (table 10). 
Table 9. Calculation of total ACER based on length of stay in the PICU room 
    
Tipikal Atypical 
Total cost 
  
IDR. 571.157 IDR. 326.091 
length of stay in the PICU room 4 Days 2 Days 
method 1. Average Cost Effectiveness Ratio 
    
Rp. 571.157/4 = 142.789,25 Rp. 326.091/2 = 163.045,5 
method 2. Incremental Cost Effectiveness Ratio 
    
No ICER calculation needed  
 
 
Table 10. Calculation of ACER antipsychotics based on length of stay in the PICU room 
    
Typical Atypical 
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method 1. Cost Effectiveness Ratio 
Drugs Cost 
  
IDR. 19.773 IDR. 12.052 
length of stay in the PICU 4 Days 2 Days 
method 2. Average Cost Effectiveness Ratio 
    
IDR. 19.773/4 = 4.943,25 IDR. 12.052/2 = 6.026 
method 3. Incremental Cost Effectiveness Ratio 
    
No ICER calculation needed 
 
ACER value in total costs based on the effectiveness with PANSS-EC score on atypical 
antipsychotics of Rp. 57,089,47 and typical antipsychotics of Rp. 1,189,910.42 (11). While 
the value of ACER costs antipsychotics based on PANSS-EC scores on atypical 
antipsychotics of Rp.21.143.86 and typical antipsychotics of Rp.41,193.75 (table 12). 
Table 11. Calculation of total ACER based on PANSS-EC score 
        Typical Atypical 
Score PANSS ≤ Average 232 250 
Total Sample 
  
479 437 
        232/479 x 100% = 48,43% 250/437 x 100% = 57,21% 
Method 1. Cost Effectiveness Ratio 
Total Cost 
  
IDR. 571.157 IDR. 326.091 
Effectiveness     0,48 0,57 
method 2. Average Cost Effectiveness Ratio  
        571.157/0,48 = 1.189.910,42 326.091/0,57 = 572.089,47 
method 3. Incremental Cost Effectiveness Ratio 
        No ICER calculation needed 
 
Table 12. Calculation of ACER antipsychotics based on PANSS-EC score 
        Typical Atypical 
Effectiveness     
  PANSS Score ≤  Average 232 250 
Total Sampel 
  
479 437 
        232/479 x 100% = 48,43% 250/437 x 100% = 57,21% 
Metode 1. Cost Effectiveness Ratio     
Cost antipsychotic IDR. 19.773 IDR. 12.052 
Efektivitas     0,48 0,57 
Metode 2. Average Cost Effectiveness Ratio 
        19.773/0,48 = 41.193,75 12.052/0,57 = 21.143,86 
Metode 3. Incremental Cost Effectiveness Ratio 
        No ICER calculation needed 
ICER Calculation (Incremental Cost-Effectiveness Ratio) 
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Based on the cost-effectiveness table (table 2.1), ICER calculation is not considered necessary 
because the typical antipsychotic has low effectiveness with high costs so it does not need to be 
considered as an alternative, and atypical antipsychotics have high effectiveness with lower costs so 
it is definitely chosen and not needed ICER calculation. Based on these data it can be concluded 
that atypical antipsychotics are more cost effective than typical antipsychotics.[5], [10]–[13]  
3.2 Discussion 
From the research data in the Jambi Provincial Hospital in 2013-2016, there were a total of 1036 
medical records. 120 of them were included in the exclusion criteria with the reason that 103 
patients had not recovered (re-hospitalized), 14 patients were discharged in a condition that had not 
recovered and 3 patients died. And 916 of 1036 medical records are data with inclusion criteria in 
which 479 patients used typical antipsychotics and 437 patients used atypical antipsychotics. 
Cost analysis is carried out by recording the price of antipsychotics per dosage form 
(tablet/ampoule), treatment costs, and the cost of doctor's actions. An intervention is said to be cost-
effective if: it is cheaper and as effective as the comparative intervention; more expensive but also 
more effective than the comparison (excess costs are proportional to the excess effectiveness 
provided); cheaper and less effective than the comparison, but the excess price of comparative 
intervention is not comparable to the excess effectiveness given [1]. 
Based on the cost-effectiveness table, typical antipsychotics are in column C where costs are higher 
with lower effectiveness. And atypical antipsychotics are in column G where lower costs with 
higher effectiveness. From the observation of the above table, it can be directly concluded that 
atypical antipsychotics are more cost effective than typical antipsychotics 
Table 13. Determination of cost analysis with cost effectiveness 
Cost-effectiveness Low cost Same Cost High cost 
Low effectiveness A B 
C 
Typical 
Same effectiveness D E F 
High effectiveness 
G 
Atypical 
H 
I 
 
 
Then to strengthen the results, ACER calculations were carried out. The value of ACER obtained 
from both the cost of antipsychotics and the total cost based on the effectiveness of length of stay 
and PANSS-EC scores showed that the ACER antipsychotic value was typically higher than 
atypical antipsychotics. So that obtaining the ACER value still shows that atypical antipsychotics 
are more cost effective than typical antipsychotics. 
Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) Vol. 02, No. 2, 2019  52 
 
Whereas ICER calculation is considered unnecessary because the typical antipsychotic has low 
effectiveness with high costs so it does not need to be considered as an alternative, and atypical 
antipsychotics have high effectiveness with lower costs so it is definitely chosen and ICER 
calculations are not needed. Based on these data it can be concluded that atypical antipsychotics are 
more cost effective than typical antipsychotics. 
4.  Conclusion 
From the results of the study, it can be concluded that atypical antipsychotics are more cost-
effective than typical antipsychotics based on PANSS-EC scores and based on length of stay. 
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